This Swedish Biotech Just Raised $15.5M to Map Proteins on Cell Surfaces

Jan de Vries · 2026-08-20

### A Big Win for Spatial Biology Stockholm's Pixelgen Technologies just closed an oversubscribed Series B round of $15.5 million (€13.26 million). For a company that emerged from stealth less than three years ago, that kind of investor enthusiasm says a lot about the potential of its technology. The round was led by new investor Flat Capital, with existing backers Industrifonden and Navigare Ventures doubling down. Along with the cash, Pixelgen is adding two heavy hitters to its board: Flat Capital CEO Rickard El Tarzi and life sciences veteran Ramon Felciano, Ph.D. ### What Does Pixelgen Actually Do? Here's where things get interesting. Most proteomic tools measure how much of a protein is present in a sample. Pixelgen's Proxiome Kit does something different—it maps where proteins are located, how they're clustered, and how they're organized on the surface of individual cells. Think of it this way: traditional proteomics tells you what's in the room. Pixelgen tells you how the furniture is arranged. This nanoscale resolution is powered by the company's Proximity Network Assay, which enables high-dimensional analysis of cell surface architecture. The implications are significant for researchers studying immunology, hematology, oncology, and cell therapy. ### Why This Matters for Drug Development The ability to see protein organization on cell surfaces opens doors that abundance measurements alone can't unlock. Disease mechanisms often involve not just how much of a protein exists, but how it's positioned relative to other proteins. That spatial context can reveal novel biomarkers and treatment response patterns that would otherwise go unnoticed. "Pixelgen's technology gives researchers the ability to study disease mechanisms and identify novel biomarkers in an entirely new way," said El Tarzi. "We believe this could open new avenues for research in cancer, immunology and autoimmune disease, while broadening our understanding of basic biology." ### The Journey So Far Pixelgen was founded in 2020 by Simon Fredriksson, Alvaro Martinez Barrio, Fredrik Dahl, and Filip Karlsson. The company emerged from stealth in December 2022 after a $6 million seed round led by Navigare Ventures. Since then, the funding trajectory has been steady: - Seed round (December 2022): $6 million - Series A (October 2023): $7.3 million - EIC Accelerator grant and equity (June 2025): $14.7 million - Series B (current): $15.5 million That's roughly $43.5 million raised in under three years—a solid vote of confidence from both private investors and the European Innovation Council. ### What's Next for Pixelgen? CEO and co-founder Fredriksson says the new capital will accelerate global commercialization of the Proxiome Kit and expand the company's presence in key markets. The plan includes growing the team, expanding the product portfolio, and bringing molecular cell architecture mapping to more researchers worldwide. With the board now including both financial and scientific expertise, Pixelgen appears well-positioned for its next phase. The combination of a differentiated platform, strong investor backing, and clear commercial traction suggests this Swedish biotech is one to watch in the spatial biology space. For researchers, the promise is simple: a new lens through which to study cell function and disease mechanisms. For investors, the bet is that this technology becomes a standard tool in the life sciences toolkit. Either way, the next few years will be telling.